Former Alibaba CEO Wei Zhe joins sansure biotech inc. Latest response: will not involve business related to mergers and acquisitions by Sanshong.

①Wei Zhe expressed that the reason for joining sansure biotech inc. was to deeply empower the medical industry and gain in-depth understanding of the medical industry; ②He recently posted on his Moments saying that his ideas are highly consistent with sansure biotech inc. and the company's director and general manager, and he will deeply cultivate the sinking medical system and layout the blueprint for going global; ③At the end of last year, Wei Zhe and his founded Jia Yu Capital began to get involved in the medical health field, and announced the establishment of Jia Yu-Ziniu Medical Fund with Ziniu Fund.

cls.cnDec 2 11:01

TJ Darentang USD: Wang Lei replaces Zhang Mingrui as the chairman, the company's development global strategy "will not change" | Speed ​​reading announcement

① Zhang Mingrui applied to resign as the chairman, director, and chairman of the global strategy committee of tj darentang usd due to work changes. ② Wang Lei, the general manager, took over as chairman, with company officials stating that the enterprise development strategy "will not change".

cls.cnNov 26 21:20

This Thursday marks the start of the "soul negotiation" for medical insurance. Which companies are likely to be selected?

According to the National Medical Insurance Administration, a press conference will be held at 10 a.m. on November 28 at the National Medical Insurance Administration to announce the adjustments to the national medical insurance pharmaceutical catalog for 2024 and answer questions from reporters. This means that the results of the national negotiation for medical insurance centralized purchasing in 2024 will be announced this Thursday.

Securities TimesNov 26 19:39

tj darentang plans to sell 13% of its stake in China and America Shire, pending antitrust review | Directly hitting the shareholder meeting.

At today's tj darentang shareholder meeting, the proposal to sell 13% equity of China-US Tianjin Shexi Pharmaceutical Co., Ltd. (referred to as China-US Shexi) to Heiliong was approved. Company chairman Zhang Mingrui said: "China-US Shexi is an excellent company, and the main reason for this equity sale is the expiration of the 40-year cooperation period." This equity sale still needs to be reviewed for anti-monopoly by the State Administration for Market Regulation on Heiliong's side.

cls.cnNov 22 19:16

Abnormal trading investigation! The big bull stock special treat Jingfeng has been suspended for the first time, with an increase of over 752% in more than four months | Quick read of the announcement.

①*ST Jingfeng suspended trading for the first time this year due to abnormal fluctuations; ② The cumulative deviation of the closing price for two consecutive trading days reached 15.39%; ③ The stock price has increased by 752.78% in the past four months; ④ There is still uncertainty about the highly anticipated pre-restructuring matters.

cls.cnNov 17 19:31

Zhangzhou Pientzehuang Pharmaceutical has acquired shares in Fujian Cosunter Pharmaceutical? The innovative drugs track sees the resurgence of players in the traditional chinese medicine industry | Speed-read announcement

fujian cosunter pharmaceutical announced that Yuanshan Fund plans to become a shareholder with a transfer payment of nearly 0.2 billion yuan, holding more than 5% of the company's shares. Yuanshan Fund partners include state-owned wholly-owned companies, zhangzhou pientzehuang pharmaceutical wholly-owned subsidiaries, among which Zhangzhou Pientzehuang Investment is the largest limited partner in terms of fund contribution proportion.

cls.cnNov 16 00:14